If I go to the brand name side first, my answer would be no. The patents worldwide are of a national treatment obligation. So we give the same patent treatment to all countries. That's good because when Canadians go abroad they want patent protection the same there. But what that means, however, just in pharmaceuticals is whether the research is done at a headquarters in New Jersey or in Europe, you would get the same protection as if you did the research in Canada. It doesn't in and of itself generate and move research to your country.
If we look at the Patented Medicine Prices Review Board over the last number of years, we've seen that despite Canada having a generous pharmaceutical patent regime, research spending in Canada by brand name pharmaceutical companies by patentees has actually been going down. So we do not think that this agreement will increase that. In fact, I don't think the Government of Canada negotiated it that way. This was seen as a defensive interest for Canada.